特立帕肽
医学
德诺苏马布
骨质疏松症
霍恩斯菲尔德秤
骨矿物
内科学
泌尿科
外科
计算机断层摄影术
作者
Anthony L. Mikula,Nikita Lakomkin,Abdelrahman M. Hamouda,Megan C. Everson,Zach Pennington,Rahul Robaish Kumar,Zachariah W. Pinter,Michael L. Martini,Mohamad Bydon,Kurt A. Kennel,Francis I. Baffour,Ahmad Nassr,Brett A. Freedman,Arjun S. Sebastian,Kingsley Abode-Iyamah,Paul A. Anderson,Jeremy L. Fogelson,Benjamin D. Elder
出处
期刊:Journal of neurosurgery
[Journal of Neurosurgery Publishing Group]
日期:2024-07-01
卷期号:: 1-7
被引量:1
标识
DOI:10.3171/2024.4.spine2424
摘要
OBJECTIVE The purpose of this study was to determine the effect of osteoporosis medications on opportunistic CT-based Hounsfield units (HU). METHODS Spine and nonspine surgery patients were retrospectively identified who had been treated with romosozumab for 3 to 12 months, teriparatide for 3 to 12 months, teriparatide for > 12 months, denosumab for > 12 months, or alendronate for > 12 months. HU were measured in the L1–4 vertebral bodies. One-way ANOVA was used to compare the mean change in HU among the five treatment regimens. RESULTS In total, 318 patients (70% women) were included, with a mean age of 69 years and mean BMI of 27 kg/m 2 . There was a significant difference in mean HU improvement (p < 0.001) following treatment with romosozumab for 3 to 12 months (n = 32), teriparatide for 3 to 12 months (n = 30), teriparatide for > 12 months (n = 44), denosumab for > 12 months (n = 123), and alendronate for > 12 months (n = 100). Treatment with romosozumab for a mean of 10.5 months significantly increased the mean HU by 26%, from a baseline of 85 to 107 (p = 0.012). Patients treated with teriparatide for > 12 months (mean 23 months) experienced a mean HU improvement of 25%, from 106 to 132 (p = 0.039). Compared with the mean baseline HU, there was no significant difference after treatment with teriparatide for 3 to 12 months (110 to 119, p = 0.48), denosumab for > 12 months (105 to 107, p = 0.68), or alendronate for > 12 months (111 to 113, p = 0.80). CONCLUSIONS Patients treated with romosozumab for a mean of 10.5 months and teriparatide for a mean of 23 months experienced improved spinal bone mineral density as estimated by CT-based opportunistic HU. Given the shorter duration of effective treatment, romosozumab may be the preferred medication for optimization of osteoporotic patients in preparation for elective spine fusion surgery.
科研通智能强力驱动
Strongly Powered by AbleSci AI